A282 DOES SERUM ADALIMUMAB LEVEL CORRELATE WITH DISEASE SEVERITY IN PATIENTS WITH CROHN’S DISEASE?
Bibliographic record
Abstract
Tests measuring serum adalimumab levels are not widely available. We aim to evaluate whether serum adalimumab levels correlate with disease severity in patients with Crohn’s disease. Additionally, as the test is expensive, we aim to see if clinical and biochemical markers can be used as a surrogate for adalimumab levels. A retrospective chart review was performed on Crohn’s disease patients that had a measured adalimumab level. Sixty-five patients were identified between January 2015 and January 2016. Disease severity was determined using the Harvey-Bradshaw Index. Patients were stratified based on their dosing intervals. For patients with weekly dosing (n=16), 8 were in remission. Mean trough adalimumab levels for remission and active disease groups were 8.8 and 7.3 respectively. There was no statistically significant relationship between trough adalimumab level and disease severity, weight, CRP or albumin. For patients with biweekly dosing (n=49), 32 were in remission. Mean trough adalimumab levels for remission and active disease groups were 8.5 and 6.1 respectively. The correlation between trough adalimumab level and weight was -0.44 (p=0.002). Similarly, the correlation between trough adalimumab level and CRP was -0.39 (p=0.031). Trough adalimumab level did not have a statistically significant relationship with albumin or disease severity. In both groups, patients in remission tended to have higher trough adalimumab levels. In patients with biweekly dosing, higher drug levels correlated with lower patient weight and lower CRP values. This likely stems from higher consumption of adalimumab with active inflammation present in active disease. The absence of statistically significant relationships for patients with weekly adalimumab dosing is likely a factor of the smaller sample size. Ultimately, larger study with prospective data may yield more helpful information. None
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.001 | 0.004 |
| Meta-epidemiology (narrow) | 0.000 | 0.000 |
| Meta-epidemiology (broad) | 0.001 | 0.001 |
| Bibliometrics | 0.001 | 0.001 |
| Science and technology studies | 0.000 | 0.000 |
| Scholarly communication | 0.001 | 0.001 |
| Open science | 0.000 | 0.000 |
| Research integrity | 0.001 | 0.001 |
| Insufficient payload (model declined to judge) | 0.002 | 0.001 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".